A Phase 3, Randomized, Open-Label, Active-Controlled, Superiority Trial of EG007, Added to the Combination of Lenvatinib Plus Pembrolizumab vs. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
Latest Information Update: 03 Aug 2023
At a glance
- Drugs EG-007 (Primary) ; Lenvatinib (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Endometrial cancer
- Focus Registrational; Therapeutic Use
- Sponsors Evergreen Therapeutics
- 26 Jul 2023 Planned End Date changed from 1 Apr 2023 to 1 Dec 2025.
- 26 Jul 2023 Planned primary completion date changed from 1 Jan 2023 to 1 Dec 2025.
- 26 Jul 2023 Planned initiation date changed from 1 Jan 2022 to 1 Dec 2024.